CommBio Therapeutics, a biotech focusing on developing intestine biology-driven novel medicine, announced strategic collaboration with Hangzhou Grand Biologic Pharmaceutical, a leading company in microbial live biotherapeutics in China
Dr. Bin Xiang has served as College Advisor of ShanghaiTech University since 2017 and participated in supervising the students in their learning of biomedical industry. During the students visit in January, Dr. Xiang gave an overview on microbiome-driven live biotherapeutics drug development and shew them around CommBio’s laboratory of bacterial genetic engineering.
Sponsored by the Shenzhen Municipal Development and Reform Commission and the Guangming District Government, and co-organized by the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, the Guangming Science City 2020 Engineering Biology Innovation Forum was held in Shenzhen on December 19, 2020. Dr. Xiang, founder of CommBio, was invited to be a panelist to discuss the status and future trends of synthetic biology in biomedicine in the "Roundtable on Synthetic Engineering in Transforming Therapy ".
Dr. Bin Xiang participated in the roundtable discussion with the Secretary of Pudong District on how to lead the future scientific and technological innovation breakthroughs at Pudong as an enterprise representative of the Zhangjiang innovative drug R&D community.
The 3rd China Bio-Pharma Partnering Forum sponsored by HEALIFE® Group was held at Xiangyuan Hilton Hotel, Hongqiao, Shanghai on December 4, 2020. Dr. Bin Xiang was invited to give a talk on new bacterial vector delivery methodologies in the field of gene therapy in the "Innovative Therapy Session".
CommBio Therapeutics Co., Ltd 沪ICP备2021004953号-1